Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Microfluidics introduces "Voice of the Customer" program

Microfluidics today introduced the "Voice of the Customer" program as part of its ongoing mission to improve communication and understanding between the company and its customers.

6 Jan 2010

"Nanoworms" and doxorubicin loaded hollow nanoparticles to fight cancer

A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors.

5 Jan 2010

A 'cocktail' to kill cancerous tumors

5 Jan 2010

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

Nanoprobes deliver drugs directly to the right tumor cellular compartments

Tiny nanoprobes have shown to be effective in delivering cancer drugs more directly to tumor cells - mitigating the damage to nearby healthy cells - and Purdue University research has shown that the nanoprobes are getting the drugs to right cellular compartments.

15 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

Rice, TMC team wins stimulus funds for nanoparticle standardization

One of the promises of nanomedicine is the design of tiny particles that can home in on diseased cells and get inside them. Nanoparticles can carry drugs into cells and tag cells for MRI and other diagnostic tests; and they may eventually even enter a cell's nucleus to repair damaged genes. Unfortunately, designing them involves as much luck as engineering.

11 Dec 2009

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.

10 Dec 2009

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA (www.anti-infectivesummit.com). This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

From IQPC Ltd 10 Dec 2009

NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.

9 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.

2 Dec 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Simulations Plus launches new version of GastroPlus

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announces the release of GastroPlus Version 6.1, the latest version of its state-of-the-art software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.

25 Nov 2009

USGS researchers examine PAHs and PCBs sources in urban environment

Toxic dust: Toxins in coal-tar-based sealcoats in parking lots may be the culprit in contaminated house dust, according to a USGS study. PAHs - or polycyclic aromatic hydrocarbons - are large molecules found in oil, coal and tar deposits, and can have toxic effects.

21 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Nanoparticle News and Research

Further Reading

Microfluidics introduces "Voice of the Customer" program

"Nanoworms" and doxorubicin loaded hollow nanoparticles to fight cancer

A 'cocktail' to kill cancerous tumors

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Researchers develop new approach for treating and healing skin abscesses

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Nanoprobes deliver drugs directly to the right tumor cellular compartments

Nanoparticle could allow diagnosis and treatment in one visit

Rice, TMC team wins stimulus funds for nanoparticle standardization

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Simulations Plus launches new version of GastroPlus

USGS researchers examine PAHs and PCBs sources in urban environment

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery